Open AccessEssential role of HDAC6 in the regulation of PD‐L1 in melanoma
Author(s) -
Lienlaf M.,
Perez-Villarroel P.,
Knox T.,
Pabon M.,
Sahakian E.,
Powers J.,
Woan K.V.,
Lee C.,
Cheng F.,
Deng S.,
Smalley K.S.M.,
Montecino M.,
Kozikowski A.,
Pinilla-Ibarz J.,
Sarnaik A.,
Seto E.,
Weber J.,
Sotomayor E.M.,
Villagra A.
Publication year - 2016
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2015.12.012
Subject(s) - hdac6 , chromatin , histone , immunosurveillance , biology , cancer research , context (archaeology) , microbiology and biotechnology , histone deacetylase , genetics , gene , tumor cells , paleontology
Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples and cell lines, down‐regulates the expression of PD‐L1, an important co‐stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD‐1 in T‐cells. Our data suggests that this novel mechanism of PD‐L1 regulation is mainly mediated by the influence of HDAC6 over the recruitment and activation of STAT3. Additionally, we observed that selective HDAC6 inhibitors impairs tumor growth and reduce the in vivo expression of several inhibitory check‐point molecules and other regulatory pathways involved in immunosurveillance. Most importantly, these results provide a key pre‐clinical rationale and justification to further study isotype selective HDAC6 inhibitors as potential immuno‐modulatory agents in cancer.